improve it or discuss these issues on the talk page . learn how and when to remove these template messages this article contains content that is written like an advertisement . please help improve it by removing promotional content and inappropriate external links and by adding encyclopedic content written from a neutral point of view . march 2016 learn how and when to remove this template message a major contributor to this article appears to have a close connection with its subject . it may require cleanup to comply with wikipedia s content policies particularly neutral point of view . please discuss further on the talk page . march 2016 learn how and when to remove this template message learn how and when to remove this template message type soci t anonyme traded as nasdaq clls allternext acls.pa industry biotechnology genome engineering oncology founded 1999 headquarters paris xiii me france new york new york united states key people michael mahoney david sourdive products engineered car t cells talen technology number of employees approximately 105 worldwide website www.cellectis.com cellectis a biopharmaceutical company focused on developing immunotherapies based on genome edited car t cells ucarts . 1 cellectis was founded in 1999 and designs novel products including immune therapies for cancer and enzymes which can add dna at targeted places in genomes . 2 contents 1 history 2 products 2.1 cancer immunotherapy 2.2 engineered nucleases 2.3 electroporation 3 references 4 external links history edit cellectis was founded by andr choulika in 1999 through a licensing agreement with the pasteur institute . in 2005 scientists working at cellectis showed that meganucleases could be used to edit a genome in vivo . 3 subsequent work led to refinements in the use of precision nucleases particularly transcription activator like tal effector nucleases talen . in 2011 cellectis acquired an exclusive license for the commercial application of talen technology from the university of minnesota and began researching the use of talen to develop engineered immune cell therapies . cellectis has been trading on alternext since 2007 and held an initial public offering on the nasdaq exchange in march 2015 . 4 not in citation given products edit cancer immunotherapy edit the company s portfolio includes several lines of proprietary chimeric antigen receptor car t cells targeting individual cancers . in 2014 cellectis entered into strategic alliances with servier and pfizer to develop and commercialize universal car t cells ucarts targeting specific cancers . as of january 2016 cellectis has five disclosed ucart products that are in various stages of clinical development . in november 2015 cellectis announced the first clinical use of its ucart technology . after she failed to respond to a traditional anti cancer regimen an 11 month old baby suffering from cd19 acute lymphoblastic leukemia was treated at the great ormond street hospital with genome edited donor t cells that had been engineered to attack leukemia cells . these cells had also been modified to be resistant to alemtuzumab and to evade detection by the host immune system after introduction . a few weeks after therapy the patient s condition improved and the patient has been in remission for several months following treatment . 5 engineered nucleases edit cellectis is a leader in the use of precision genome editing technologies including meganucleases tal effector nucleases talen and megatals which combine the benefits of both meganucleases and talen constructs . the use of these technologies allows for predictable and accurate gene editing . electroporation edit cellectis acquired cyto pulse in 2010 a company that had developed new electroporation technology that allows mrna and dna to be incorporated into cells with precise pulses of electricity . 6 references edit bryce elder ; arash massoud ; andrew ward ; david crow 2015 05 28 . biotech cellectis in takeover talks with pfizer . financial times . retrieved 2016 03 16 . subscription required help . how servier saved cellectis the french car t miracle . labiotech.eu . 2015 07 15 . retrieved 2016 03 16 . history cellectis . www.cellectis.com . retrieved 2016 01 14 . cellectis january 2016 corporate presentation pdf . cellectis s.a. retrieved 2016 01 13 . paper first clinical application of talen engineered universal car19 t cells in b all . ash.confex.com . retrieved 2016 01 28 . dead link genetic engineering & biotechnology news biotech from bench to business . genengnews.com . 2013 11 08 . retrieved 2016 03 16 . dead link external links edit cellectis retrieved from https en.wikipedia.org w index.php title cellectis & oldid 740815309 categories companies of francebiotechnology companies of francecompanies listed on the euronext exchangescompanies established in 1999companies listed on nasdaqhidden categories pages containing links to subscription only contentall articles with dead external linksarticles with dead external links from september 2016articles with a promotional tone from march 2016all articles with a promotional tonewikipedia articles with possible conflicts of interest from march 2016all articles with failed verificationarticles with failed verification from september 2015 navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages fran ais edit links this page was last modified on 23 september 2016 at 13 28 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view